

Elena Campello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2575328/publications.pdf>

Version: 2024-02-01

127
papers

3,166
citations

159358

30
h-index

189595

50
g-index

130
all docs

130
docs citations

130
times ranked

4472
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. <i>Thrombosis and Haemostasis</i> , 2020, 120, 998-1000.	1.8	553
2	Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1474-1477.	1.8	233
3	Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. <i>Thrombosis Research</i> , 2011, 127, 473-477.	0.8	122
4	Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. <i>Thrombosis and Haemostasis</i> , 2015, 113, 85-96.	1.8	82
5	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. <i>British Journal of Cancer</i> , 2019, 121, 359-371.	2.9	78
6	Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26901.	5.5	69
7	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.4	66
8	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypocoagulable and Hypercoagulable Features. <i>Hepatology</i> , 2020, 72, 1327-1340.	3.6	60
9	Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients. <i>Thrombosis Research</i> , 2015, 135, 548-553.	0.8	59
10	Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. <i>Thrombosis and Haemostasis</i> , 2013, 110, 378-385.	1.8	55
11	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. <i>Cardiovascular Diabetology</i> , 2017, 16, 118.	2.7	55
12	Thrombophilia, risk factors and prevention. <i>Expert Review of Hematology</i> , 2019, 12, 147-158.	1.0	54
13	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	1.7	51
14	New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1022-1029.	1.1	49
15	Microparticles as biomarkers of venous thromboembolic events. <i>Biomarkers in Medicine</i> , 2016, 10, 743-755.	0.6	46
16	COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward. <i>Clinical and Translational Science</i> , 2020, 13, 1108-1114.	1.5	46
17	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 251-265.	1.8	44
18	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	1.8	43

#	ARTICLE	IF	CITATIONS
19	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	1.8	41
20	Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1323-1330.	1.4	40
21	Diagnosis and management of factor V Leiden. <i>Expert Review of Hematology</i> , 2016, 9, 1139-1149.	1.0	39
22	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	1.9	39
23	Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluoro-Octanoic Acid: Role of Impaired Platelet Aggregation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 399.	1.8	39
24	Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. <i>Thrombosis and Haemostasis</i> , 2016, 115, 81-88.	1.8	36
25	Dynamics of circulating microparticles in obesity after weight loss. <i>Internal and Emergency Medicine</i> , 2016, 11, 695-702.	1.0	34
26	Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 334-341.	0.7	34
27	Diagnosis and Treatment of Trauma-Induced Coagulopathy by Viscoelastography. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 134-146.	1.5	33
28	Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1188-1192.	1.8	32
29	Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. <i>Thrombosis Research</i> , 2015, 136, 427-431.	0.8	32
30	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti- β_2 glycoprotein I antibodies. A comparison with a homemade ELISA method. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1083-9.	1.4	32
31	ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia. <i>Blood Transfusion</i> , 2013, 11, 250-3.	0.3	32
32	Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018917.	1.6	31
33	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , 2016, 143, 118-121.	0.8	29
34	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	1.9	29
35	Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2012, 108, 633-639.	1.8	27
36	Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 770463.	1.8	27

#	ARTICLE	IF	CITATIONS
37	Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. <i>Minerva Anestesiologica</i> , 2019, 85, 625-634.	0.6	26
38	Whole blood rotation thromboelastometry (ROTEM [®]) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. <i>Haemophilia</i> , 2012, 18, 463-468.	1.0	24
39	Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. <i>Thrombosis Research</i> , 2014, 134, 259-263.	0.8	23
40	The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. <i>Internal and Emergency Medicine</i> , 2017, 12, 981-991.	1.0	23
41	Development and application of global assays of hyper- and hypofibrinolysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 46-53.	1.0	23
42	Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. <i>Thrombosis Research</i> , 2021, 205, 24-28.	0.8	22
43	Optimal duration of anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1210-1215.	1.8	21
44	Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation. <i>Scientific Reports</i> , 2020, 10, 11910.	1.6	21
45	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	1.7	21
46	Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 534-537.	0.5	20
47	Partial <i>F8</i> gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. <i>Blood</i> , 2021, 137, 2383-2393.	0.6	20
48	Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 654-661.	1.5	19
49	Thrombophilia and the risk of post-thrombotic syndrome: retrospective cohort observation. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 211-213.	1.9	18
50	Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery. <i>Internal and Emergency Medicine</i> , 2016, 11, 793-801.	1.0	18
51	The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement. <i>Artificial Organs</i> , 2016, 40, 698-705.	1.0	18
52	In vitro correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. <i>Haemophilia</i> , 2018, 24, 648-656.	1.0	18
53	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 879-888.	0.4	17
54	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	1.9	17

#	ARTICLE	IF	CITATIONS
55	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	2.6	17
56	Whole blood thromboelastometry profiles in women with preeclampsia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1793-8.	1.4	16
57	Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 487-495.	0.6	16
58	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	2.0	16
59	Circulating microparticles in carriers of prothrombin G20210A mutation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 432-437.	1.8	14
60	Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease. <i>Endocrine</i> , 2018, 62, 207-214.	1.1	14
61	Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 484-488.	1.4	13
62	Whole-blood hypocoagulable profile correlates with a greater risk of death within 28 days in patients with severe sepsis. <i>Korean Journal of Anesthesiology</i> , 2020, 73, 224-231.	0.9	13
63	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. <i>Rheumatology</i> , 2022, 61, S1136-S1142.	0.9	13
64	Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1231-1234.	1.8	12
65	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	1.9	12
66	More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 696-702.	1.2	12
67	Platelet-Derived Microparticles Bearing PF4 and Anti-GAGS Immunoglobulins in Patients with Sepsis. <i>Diagnostics</i> , 2020, 10, 627.	1.3	12
68	Factor VIIa-antithrombin complexes in children with ischemic stroke. <i>Thrombosis Research</i> , 2011, 128, 303-304.	0.8	10
69	Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. <i>Xenotransplantation</i> , 2013, 20, 89-99.	1.6	9
70	Clinical and laboratory characteristics of isolated lupus anticoagulants. <i>Thrombosis Research</i> , 2018, 165, 51-53.	0.8	9
71	Mechanisms of thrombosis in pancreatic ductal adenocarcinoma. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101346.	0.7	9
72	Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2205-2206.	1.9	8

#	ARTICLE	IF	CITATIONS
73	“Hypocoagulable” thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts?. <i>International Journal of Cardiology</i> , 2013, 168, 2914.	0.8	8
74	Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study. <i>Thrombosis Research</i> , 2017, 153, 85-89.	0.8	8
75	Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism. <i>Thrombosis Research</i> , 2013, 132, 484-486.	0.8	7
76	ABO blood group and the risk of post-thrombotic syndrome. <i>Annals of Hematology</i> , 2018, 97, 1057-1060.	0.8	7
77	Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study. <i>Blood Advances</i> , 2020, 4, 5442-5448.	2.5	7
78	Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: Risk Factors and Prevention. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 914-919.	1.5	7
79	Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. <i>Viruses</i> , 2022, 14, 737.	1.5	7
80	Prothrombin Mutation Conveying Antithrombin Resistance. <i>New England Journal of Medicine</i> , 2012, 367, 1069-1070.	13.9	6
81	Endocytosis of exogenous factor V by <i>in vivo</i> differentiated megakaryocytes from patients with severe parahaemophilia. <i>British Journal of Haematology</i> , 2016, 175, 517-524.	1.2	6
82	Short-term exposure to high levels of air pollution (nickel) and the risk of acute unprovoked proximal deep vein thrombosis in the legs. <i>Internal and Emergency Medicine</i> , 2016, 11, 159-162.	1.0	6
83	The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 997-1003.	1.0	6
84	Hemostatic changes in pregnancy. <i>Reviews in Health Care</i> , 2013, 4, 31-39.	0.1	6
85	Risk Factors for Post-Thrombotic Syndrome in Patients With a First Proximal Deep Venous Thrombosis Treated With Direct Oral Anticoagulants. <i>Angiology</i> , 2022, 73, 649-654.	0.8	6
86	Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1352-1360.	1.8	6
87	Reply to “Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis”. <i>Platelets</i> , 2022, 33, 1104-1106.	1.1	6
88	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 709-711.	0.5	5
89	Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 934-943.	1.4	5
90	Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 501-504.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa. <i>Thrombosis Research</i> , 2018, 170, 133-141.	0.8	5
92	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 795-798.	1.0	5
93	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.4	5
94	Hyperacute Valve Thrombosis After Transapical Transcatheter Aortic Valve Replacement in a Patient With Polycythemia Vera. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1746-1747.	1.1	4
95	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018, 36, 801-803.	0.8	4
96	The prognostic role of ThromboDynamic Index in patients with severe sepsis. <i>Internal and Emergency Medicine</i> , 2020, 15, 163-168.	1.0	4
97	Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 127-131.	0.5	4
98	Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery. <i>Blood Transfusion</i> , 2021, 19, 144-151.	0.3	4
99	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. <i>Thrombosis Research</i> , 2012, 129, 818-819.	0.8	3
100	Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders. <i>Haemophilia</i> , 2018, 24, e428-e430.	1.0	3
101	Thrombotic risk following video-assisted thoracoscopic surgery versus open thoracotomy: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 573-581.	0.5	3
102	Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients. <i>Thrombosis Research</i> , 2017, 156, 20-22.	0.8	3
103	Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 755-756.	1.8	2
104	Peculiar laboratory phenotype/ genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism. <i>Hamostaseologie</i> , 2018, 38, 33-38.	0.9	2
105	Thromboelastometry profiles after <i>in vitro</i> addition of a new plasma-derived factor V concentrate to whole blood from parahaemophilia patients. <i>Haemophilia</i> , 2019, 25, e38-e42.	1.0	2
106	Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point-of-care testing to assess hemostatic competence. <i>Transfusion</i> , 2020, 60, S101-S121.	0.8	2
107	The haemostatic system in acromegaly: a single-centre case-control study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1009-1018.	1.8	2
108	Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12678.	1.0	2

#	ARTICLE	IF	CITATIONS
109	Treatment of venous thromboembolism: the single-drug approach. <i>Clinical Practice (London, England)</i> , 2019, 19, 107-111.	0.784314	1
110	On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 281-286.	0.6	1
111	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	0.8	1
112	Reply to "Acute kidney injury in patients with decompensated cirrhosis". <i>Digestive and Liver Disease</i> , 2021, 53, 1217-1218.	0.4	1
113	ABO blood groups and the risk of retinal vein occlusion. <i>Internal and Emergency Medicine</i> , 2021, 16, 1387-1390.	1.0	1
114	Antithrombin Plasma Levels and Fibrin Determination in Children with Acute Lymphoblastic Leukemia Undergoing Asparaginase Treatment. <i>Blood</i> , 2014, 124, 5246-5246.	0.6	1
115	Thromboelastometry-guided therapy of massive gastrointestinal bleeding in a 12-year old boy with severe Graft-versus-Host disease. <i>Blood Transfusion</i> , 2015, 13, 320-3.	0.3	1
116	Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , 2022, 76, E16-E17.	3.6	1
117	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.4	0
118	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.4	0
119	Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution. <i>Journal of Hepatology</i> , 2017, 66, S122.	1.8	0
120	Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment. <i>Journal of Hepatology</i> , 2018, 68, S538-S539.	1.8	0
121	New generation flow-cytometry to measure circulating microvesicles in cancer. <i>Thrombosis Research</i> , 2018, 164, S242-S243.	0.8	0
122	The diagnostic challenge: are we missing pulmonary embolism diagnosis in patients with syncope?. <i>Internal and Emergency Medicine</i> , 2018, 13, 965-969.	1.0	0
123	Heparin challenge test in patients undergoing cardiac surgery: dealing with heparin allergy. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 165-169.	0.5	0
124	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: A new potential therapeutic target?. <i>Digestive and Liver Disease</i> , 2021, 53, S37-S38.	0.4	0
125	PO-29 Plasma levels of procoagulant and anticoagulant factors in patients with acute cancer-associated thrombosis. <i>Thrombosis Research</i> , 2021, 200, S32.	0.8	0
126	Could Hemorrhagic and Thrombotic Risk Due to Peg-Asparaginase be Identified By Coagulative Tests Using Fibrinogen and Antithrombin Levels? A Single Centre Study. <i>Blood</i> , 2015, 126, 2305-2305.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Increased platelet aggregation in decompensated cirrhosis indicates higher risks of further decompensation and liver-related mortality. Digestive and Liver Disease, 2022, 54, S16-S17.	0.4	0